Skip to main content
SpringerLink
Log in
Book cover

Frontiers in Psychiatry pp 313–329Cite as

Psychopharmacology and Psychotherapy Research

  • Chapter
  • First Online:

  • 3034 Accesses

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1192))

Abstract

With vigorous researches related to novel treatment in psychiatric field, paradigm shift is emerging with its design and assessment. Comprehension of the psychiatric phenomenon expanded beyond disease model, with dimensional approach. Assessment of patients’ clinical state includes subjective reports related to problematic symptoms, functional change, and quality of life. They also include objective findings collected from mobile e-wearable monitoring system and advanced neuroimaging modalities. Novel treatment protocols are not just limited to pharmacology itself or psychotherapy itself, but the approach is integrated with stratification; pharmacological treatment enhanced by cognitive behavioral management and psychotherapeutic intervention has been emerged and studied for its impact. Numerous studies were conducted to understand placebo response and to differentiate this phenomenon with novel treatments. Trials to draw good adherence to research protocol with good compliance to treatment in real are strengthened by integrated approach, so-called psychopharmacology. With these paradigm shifts observed from recent researches, it is promising for great advance in quality of life and our mental health.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Feinstein AR, Horwitz RI. Problems in the “evidence” of “evidence-based medicine”. Am J Med. 1997;103(6):529–35.

    Article  CAS  PubMed  Google Scholar 

  2. Tomba E, Rafanelli C, Grandi S, Guidi J, Fava GA. Clinical configuration of cyclothymic disturbances. J Affect Disord. 2012;139(3):244–9.

    Article  PubMed  Google Scholar 

  3. Lavori PW, Dawson R. Adaptive treatment strategies in chronic disease. Annu Rev Med. 2008;59:443–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Tomba E, Bech P. Clinimetrics and clinical psychometrics: macro- and micro-analysis. Psychother Psychosom. 2012;81(6):333–43.

    Article  PubMed  Google Scholar 

  5. Moller HJ. Standardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales. World J Biol Psychiatry: Off J World Fed Soc Biol Psychiatry. 2009;10(1):6–26.

    Article  Google Scholar 

  6. Castelnuovo G. New and old adventures of clinical health psychology in the twenty-first century: standing on the shoulders of giants. Front Psychol. 2017;8:1214.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Harmer CJ, Cowen PJ, Goodwin GM. Efficacy markers in depression. J Psychopharmacol. 2011;25(9):1148–58.

    Article  CAS  PubMed  Google Scholar 

  8. Dutcher JM, Creswell JD. Behavioral interventions in health neuroscience. Ann N Y Acad Sci. 2018;1428(1):51–70.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Malaspina D, Walsh-Messinger J, Gaebel W, Smith LM, Gorun A, Prudent V, et al. Negative symptoms, past and present: a historical perspective and moving to DSM-5. Eur Neuropsychopharmacol. 2014;24(5):710–24.

    Article  CAS  PubMed  Google Scholar 

  10. Bobes J, Arango C, Garcia-Garcia M, Rejas J, Group CSC. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010;71(3):280–6.

    Article  Google Scholar 

  11. Linden D. Biological psychiatry: time for new paradigms. Br J Psychiatry: J Ment Sci. 2013;202(3):166–7.

    Article  Google Scholar 

  12. 19th Workshop of the international stroke genetics consortium, April 28–29, 2016, Boston, Massachusetts, USA: 2016.001 MRI-defined cerebrovascular genomics-the CHARGE consortium. Neurol Genet. 2017;3(1 Suppl 1):S2–S11.

    Google Scholar 

  13. Schumann G, Loth E, Banaschewski T, Barbot A, Barker G, Buchel C, et al. The IMAGEN study: reinforcement-related behaviour in normal brain function and psychopathology. Mol Psychiatry. 2010;15(12):1128–39.

    Article  CAS  PubMed  Google Scholar 

  14. Thompson PM, Andreassen OA, Arias-Vasquez A, Bearden CE, Boedhoe PS, Brouwer RM, et al. ENIGMA and the individual: predicting factors that affect the brain in 35 countries worldwide. Neuroimage. 2017;145(Pt B):389–408.

    Article  PubMed  Google Scholar 

  15. Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry. 2012;17(2):142–53.

    Article  CAS  PubMed  Google Scholar 

  16. Uhlhaas PJ, Liddle P, Linden DEJ, Nobre AC, Singh KD, Gross J. Magnetoencephalography as a tool in psychiatric research: current status and perspective. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017;2(3):235–44.

    Article  PubMed  PubMed Central  Google Scholar 

  17. IsHak WW, Mirocha J, Christensen S, Wu F, Kwock R, Behjat J, et al. Patient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the star*d trial. Depress Anxiety. 2014;31(8):707–16.

    Article  PubMed  Google Scholar 

  18. Scarr E, Millan MJ, Bahn S, Bertolino A, Turck CW, Kapur S, et al. Biomarkers for psychiatry: the journey from fantasy to fact, a report of the 2013 CINP think tank. Int J Neuropsychopharmacol. 2015;18(10):pyv042.

    Google Scholar 

  19. Eichler HG, Bloechl-Daum B, Brasseur D, Breckenridge A, Leufkens H, Raine J, et al. The risks of risk aversion in drug regulation. Nat Rev Drug Discov. 2013;12(12):907–16.

    Article  CAS  PubMed  Google Scholar 

  20. Possemato K, Johnson EM, Beehler GP, Shepardson RL, King P, Vair CL, et al. Patient outcomes associated with primary care behavioral health services: a systematic review. Gen Hosp Psychiatry. 2018;53:1–11.

    Article  PubMed  Google Scholar 

  21. Csipke E, Williams P, Rose D, Koeser L, McCrone P, Wykes T, et al. Following the Francis report: investigating patient experience of mental health in-patient care. Br J Psychiatry: J Ment Sci. 2016;209(1):35–9.

    Article  CAS  Google Scholar 

  22. Mathie E, Wythe H, Munday D, Rhodes G, Vicary P, Millac P, et al. Regional working in the east of England: using the UK national standards for public involvement. Res Involv Engagem. 2018;4:48.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Howe A. Principles of patient and public involvement in primary care research, applied to mental health research. A keynote paper from the EGPRN autumn conference 2017 in Dublin. Eur J Gen Pract. 2018;24(1):167–70.

    Article  Google Scholar 

  24. Swildens WE, Visser E, Bahler M, Bruggeman R, Delespaul P, van der Gaag M, et al. Functional recovery of individuals with serious mental illnesses: development and testing of a new short instrument for routine outcome monitoring. Psychiatr Rehabil J. 2018;41(4):341–50.

    Article  PubMed  Google Scholar 

  25. Wojtalik JA, Smith MJ, Keshavan MS, Eack SM. A Systematic and meta-analytic review of neural correlates of functional outcome in schizophrenia. Schizophr Bull. 2017;43(6):1329–47.

    Article  PubMed  PubMed Central  Google Scholar 

  26. de Zwart PL, Jeronimus BF, de Jonge P. Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review. Epidemiol Psychiatr Sci. 2018:1–19.

    Google Scholar 

  27. Gambino M, Pavlo A, Ross DA. Recovery in mind: perspectives from postgraduate psychiatric trainees. Acad Psychiatry. 2016;40(3):481–8.

    Article  PubMed  Google Scholar 

  28. Schawo S, Bouwmans C, van der Schee E, Hendriks V, Brouwer W, Hakkaart L. The search for relevant outcome measures for cost-utility analysis of systemic family interventions in adolescents with substance use disorder and delinquent behavior: a systematic literature review. Health Qual Life Outcomes. 2017;15(1):179.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Bateman DR, Srinivas B, Emmett TW, Schleyer TK, Holden RJ, Hendrie HC, et al. Categorizing health outcomes and efficacy of mHealth apps for persons with cognitive impairment: a systematic review. J Med Internet Res. 2017;19(8):e301.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Meerwijk EL, Parekh A, Oquendo MA, Allen IE, Franck LS, Lee KA. Direct versus indirect psychosocial and behavioural interventions to prevent suicide and suicide attempts: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(6):544–54.

    Article  PubMed  Google Scholar 

  31. Andrews G, Basu A, Cuijpers P, Craske MG, McEvoy P, English CL, et al. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: an updated meta-analysis. J Anxiety Disord. 2018;55:70–8.

    Article  CAS  PubMed  Google Scholar 

  32. Lei H, Nahum-Shani I, Lynch K, Oslin D, Murphy SA. A “SMART” design for building individualized treatment sequences. Annu Rev Clin Psychol. 2012;8:21–48.

    Article  CAS  PubMed  Google Scholar 

  33. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–17.

    Article  PubMed  Google Scholar 

  34. Gelenberg AJ, Thase ME, Meyer RE, Goodwin FK, Katz MM, Kraemer HC, et al. The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry. 2008;69(10):1513–28.

    Article  PubMed  Google Scholar 

  35. Prisciandaro JJ, Tolliver BK. An item response theory evaluation of the young mania rating scale and the montgomery-asberg depression rating scale in the systematic treatment enhancement program for bipolar disorder (STEP-BD). J Affect Disord. 2016;205:73–80.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Pereira Junior Bde S, Tortella G, Lafer B, Nunes P, Bensenor IM, Lotufo PA, et al. The bipolar depression electrical treatment trial (BETTER): design, rationale, and objectives of a randomized, sham-controlled trial and data from the pilot study phase. Neural Plast. 2015;2015:684025.

    Article  CAS  Google Scholar 

  37. Farmer C, Thurm A, Grant P. Pharmacotherapy for the core symptoms in autistic disorder: current status of the research. Drugs. 2013;73(4):303–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Owen DR, Rupprecht R, Nutt DJ. Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety? J Psychopharmacol. 2013;27(2):119–22.

    Article  PubMed  Google Scholar 

  39. Fernandes BS, Williams LM, Steiner J, Leboyer M, Carvalho AF, Berk M. The new field of ‘precision psychiatry’. BMC Med. 2017;15(1):80.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Schumann G, Binder EB, Holte A, de Kloet ER, Oedegaard KJ, Robbins TW, et al. Stratified medicine for mental disorders. Eur Neuropsychopharmacol. 2014;24(1):5–50.

    Article  CAS  PubMed  Google Scholar 

  41. Millan MJ. On ‘polypharmacy’ and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. Int J Neuropsychopharmacol. 2014;17(7):1009–37.

    Article  CAS  PubMed  Google Scholar 

  42. Nikolic K, Mavridis L, Djikic T, Vucicevic J, Agbaba D, Yelekci K, et al. Drug design for CNS diseases: polypharmacological profiling of compounds using cheminformatic, 3D-QSAR and virtual screening methodologies. Front Neurosci. 2016;10:265.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Wong EH, Tarazi FI, Shahid M. The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action. Pharmacol Ther. 2010;126(2):173–85.

    Article  CAS  PubMed  Google Scholar 

  44. Ballon J, Stroup TS. Polypharmacy for schizophrenia. Curr Opin Psychiatry. 2013;26(2):208–13.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 2012;35(1):47–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Duman RS. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress Anxiety. 2014;31(4):291–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Zhou Y, Peng Y, Fang J, Sun W, Zhang G, Zhen L, et al. Effect of low-dose ketamine on perioperative depressive symptoms in patients undergoing intracranial tumor resection (PASSION): study protocol for a randomized controlled trial. Trials. 2018;19(1):463.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, et al. Synaptic loss and the pathophysiology of PTSD: implications for ketamine as a prototype novel therapeutic. Curr Psychiatry Rep. 2017;19(10):74.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Kim YK, Choi J, Park SC. A novel bio-psychosocial-behavioral treatment model in schizophrenia. Int J Mol Sci. 2017;18(4): pii: E734..

    Article  PubMed Central  CAS  Google Scholar 

  50. Miyashiro KY, Bell TJ, Sul JY, Eberwine J. Subcellular neuropharmacology: the importance of intracellular targeting. Trends Pharmacol Sci. 2009;30(4):203–11.

    Article  CAS  PubMed  Google Scholar 

  51. Arlt AD, Nestoriuc Y, Rief W. Why current drug adherence programs fail: addressing psychological risk factors of nonadherence. Curr Opin Psychiatry. 2017;30(5):326–33.

    Article  PubMed  Google Scholar 

  52. Sajatovic M, Ramirez LF, Fuentes-Casiano E, Cage J, Tatsuoka C, Aebi ME, et al. A 6-month prospective trial of a personalized behavioral intervention+ long-acting injectable antipsychotic in individuals with schizophrenia at risk of treatment nonadherence and homelessness. J Clin Psychopharmacol. 2017;37(6):702–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Pakpour AH, Modabbernia A, Lin CY, Saffari M, Ahmadzad Asl M, Webb TL. Promoting medication adherence among patients with bipolar disorder: a multicenter randomized controlled trial of a multifaceted intervention. Psychol Med. 2017;47(14):2528–39.

    Article  CAS  PubMed  Google Scholar 

  54. Averous P, Charbonnier E, Lagouanelle-Simeoni MC, Prosperi A, Dany L. Illness perceptions and adherence in bipolar disorder: an exploratory study. Compr Psychiatry. 2018;80:109–15.

    Article  PubMed  Google Scholar 

  55. Tessier A, Boyer L, Husky M, Bayle F, Llorca PM, Misdrahi D. Medication adherence in schizophrenia: the role of insight, therapeutic alliance and perceived trauma associated with psychiatric care. Psychiatry Res. 2017;257:315–21.

    Article  PubMed  Google Scholar 

  56. Sirey JA, Banerjee S, Marino P, Bruce ML, Halkett A, Turnwald M, et al. Adherence to depression treatment in primary care: a randomized clinical trial. JAMA Psychiatry. 2017;74(11):1129–35.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Baeza-Velasco C, Olie E, Beziat S, Guillaume S, Courtet P. Determinants of suboptimal medication adherence in patients with a major depressive episode. Depress Anxiety. 2018. https://doi.org/10.1002/da.22852. [Epub ahead of print].

    Article  PubMed  Google Scholar 

  58. Etain B, Scott J, Cochet B, Bellivier F, Boudebesse C, Drancourt N, et al. A study of the real-world effectiveness of group psychoeducation for bipolar disorders: is change in illness perception a key mediator of benefit? J Affect Disord. 2018;227:713–20.

    Article  CAS  PubMed  Google Scholar 

  59. Olfson M, Kroenke K, Wang S, Blanco C. Trends in office-based mental health care provided by psychiatrists and primary care physicians. J Clin Psychiatry. 2014;75(3):247–53.

    Article  PubMed  Google Scholar 

  60. Olfson M, Blanco C, Wang S, Laje G, Correll CU. National trends in the mental health care of children, adolescents, and adults by office-based physicians. JAMA Psychiatry. 2014;71(1):81–90.

    Article  PubMed  Google Scholar 

  61. Wolpert M, Dalzell K, Ullman R, Garland L, Cortina M, Hayes D, et al. Strategies not accompanied by a mental health professional to address anxiety and depression in children and young people: a scoping review of range and a systematic review of effectiveness. Lancet Psychiatry. 2019;6(1):46–60.

    Article  PubMed  Google Scholar 

  62. Davies EB, Morriss R, Glazebrook C. Computer-delivered and web-based interventions to improve depression, anxiety, and psychological well-being of university students: a systematic review and meta-analysis. J Med Internet Res. 2014;16(5):e130.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Simon J, Budge K, Price J, Goodwin GM, Geddes JR. Remote mood monitoring for adults with bipolar disorder: an explorative study of compliance and impact on mental health service use and costs. Eur Psychiatry. 2017;45:14–9.

    Article  CAS  PubMed  Google Scholar 

  64. Niendam TA, Tully LM, Iosif AM, Kumar D, Nye KE, Denton JC, et al. Enhancing early psychosis treatment using smartphone technology: a longitudinal feasibility and validity study. J Psychiatr Res. 2018;96:239–46.

    Article  PubMed  Google Scholar 

  65. Rootes-Murdy K, Glazer KL, Van Wert MJ, Mondimore FM, Zandi PP. Mobile technology for medication adherence in people with mood disorders: a systematic review. J Affect Disord. 2018;227:613–7.

    Article  PubMed  Google Scholar 

  66. Depp CA, Ceglowski J, Wang VC, Yaghouti F, Mausbach BT, Thompson WK, et al. Augmenting psychoeducation with a mobile intervention for bipolar disorder: a randomized controlled trial. J Affect Disord. 2015;174:23–30.

    Article  PubMed  Google Scholar 

  67. Hennemann S, Farnsteiner S, Sander L. Internet- and mobile-based aftercare and relapse prevention in mental disorders: a systematic review and recommendations for future research. Internet Interv. 2018;14:1–17.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Myin-Germeys I, Kasanova Z, Vaessen T, Vachon H, Kirtley O, Viechtbauer W, et al. Experience sampling methodology in mental health research: new insights and technical developments. World Psychiatry. 2018;17(2):123–32.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Rotondi AJ, Anderson CM, Haas GL, Eack SM, Spring MB, Ganguli R, et al. Web-based psychoeducational intervention for persons with schizophrenia and their supporters: one-year outcomes. Psychiatr Serv. 2010;61(11):1099–105.

    Article  PubMed  Google Scholar 

  70. Hatch A, Docherty JP, Carpenter D, Ross R, Weiden PJ. Expert consensus survey on medication adherence in psychiatric patients and use of a digital medicine system. J Clin Psychiatry. 2017;78(7):e803–12.

    Article  PubMed  Google Scholar 

  71. Zubieta JK, Stohler CS. Neurobiological mechanisms of placebo responses. Ann N Y Acad Sci. 2009;1156:198–210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Pecina M, Zubieta JK. Molecular mechanisms of placebo responses in humans. Mol Psychiatry. 2015;20(4):416–23.

    Article  CAS  PubMed  Google Scholar 

  73. Gourion D, Mouchabac S. Placebo effect: clinical, biological and therapeutical involvements in depression. Encephale. 2016;42(1 Suppl 1):1S24–30.

    Google Scholar 

  74. Furukawa TA, Cipriani A, Atkinson LZ, Leucht S, Ogawa Y, Takeshima N, et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry. 2016;3(11):1059–66.

    Article  PubMed  Google Scholar 

  75. Khan A, Fahl Mar K, Faucett J, Khan Schilling S, Brown WA. Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US food and drug administration 1987–2013. World Psychiatry. 2017;16(2):181–92.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Furukawa TA, Cipriani A, Leucht S, Atkinson LZ, Ogawa Y, Takeshima N, et al. Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy. Evid Based Ment Health. 2018;21(1):1–3.

    Article  PubMed  Google Scholar 

  77. Weimer K, Colloca L, Enck P. Placebo eff ects in psychiatry: mediators and moderators. Lancet Psychiatry. 2015;2(3):246–57.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Geers AL, Miller FG. Understanding and translating the knowledge about placebo effects: the contribution of psychology. Curr Opin Psychiatry. 2014;27(5):326–31.

    Article  PubMed  Google Scholar 

  79. Dodd S, Dean OM, Vian J, Berk M. A review of the theoretical and biological understanding of the nocebo and placebo phenomena. Clin Ther. 2017;39(3):469–76.

    Article  PubMed  Google Scholar 

  80. Colagiuri B, Schenk LA, Kessler MD, Dorsey SG, Colloca L. The placebo effect: from concepts to genes. Neuroscience. 2015;307:171–90.

    Article  CAS  PubMed  Google Scholar 

  81. Blease CR. Psychotherapy and placebos: manifesto for conceptual clarity. Front Psychiatry. 2018;9:379.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115–27.

    Article  PubMed  Google Scholar 

  83. Tamura RN, Huang X. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. Clin Trials. 2007;4(4):309–17.

    Article  PubMed  Google Scholar 

  84. Silverman RK, Ivanova A. Sample size re-estimation and other midcourse adjustments with sequential parallel comparison design. J Biopharm Stat. 2017;27(3):416–25.

    Article  PubMed  Google Scholar 

  85. Muller U, Fletcher PC, Steinberg H. The origin of pharmacopsychology: Emil Kraepelin’s experiments in Leipzig, Dorpat and Heidelberg (1882–1892). Psychopharmacology. 2006;184(2):131–8.

    Article  PubMed  CAS  Google Scholar 

  86. Guidi J, Fava GA. Emerging trends in clinical psychology. Riv Psichiatr. 2014;49(6):227.

    PubMed  Google Scholar 

  87. Bech P. Applied psychometrics in clinical psychiatry: the pharmacopsychometric triangle. Acta Psychiatr Scand. 2009;120(5):400–9.

    Article  CAS  PubMed  Google Scholar 

  88. Richardson WS, Doster LM. Comorbidity and multimorbidity need to be placed in the context of a framework of risk, responsiveness, and vulnerability. J Clin Epidemiol. 2014;67(3):244–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Veteran Health Service Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    Kiwon Kim

  2. Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    Hong Jin Jeon

Authors
  1. Kiwon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong Jin Jeon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong Jin Jeon .

Editor information

Editors and Affiliations

  1. College of Medicine, Korea University, Seoul, Gyeonggi-do, Korea (Republic of)

    Yong-Ku Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kim, K., Jeon, H.J. (2019). Psychopharmacology and Psychotherapy Research. In: Kim, YK. (eds) Frontiers in Psychiatry. Advances in Experimental Medicine and Biology, vol 1192. Springer, Singapore. https://doi.org/10.1007/978-981-32-9721-0_16

Download citation

Publish with us

Policies and ethics

Search

Navigation